Health Trials

Predictors and Prognostic Factors of Myasthenia Gravis Outcome

ConditionsMyasthenia GravisAutoimmune Diseases of the Nervous SystemNeuromuscular Junction DiseasesThymomaThymus HyperplasiaNervous System DiseasesMyasthenia Gravis, GeneralizedMyasthenia Gravis, OcularMyasthenia Gravis CrisisMyasthenia Gravis With Exacerbation (Disorder)Myasthenia Gravis, Adult FormMyasthenia Gravis, Juvenile Form
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age16+
SponsorAssiut University

About this trial

This study aims to characterize the clinical features, frequency of different subgroups of MG, and identify predictors of treatment responsiveness among different subgroups of MG. The predictors are including primary outcome (percentage of changes in MG scales at baseline at time of enrollment and after 3 months) and secondary outcome (treatment-related adverse events). Also it aims to determine the frequency of patients with refractory MG.

This information will be used to understand the trends and mechanisms of disease relapse, and optimal management strategies.

Eligibility criteria

Qualifiers

Age from 16 years and older.

Gender: both sexes are included.

unequivocal clinical response to pyridostigmine

decrement >10% in repetitive nerve stimulations study (RNS).

Disqualifiers

Age younger than 16 years.

History of chronic psychiatric or neurological disorder other than MG that can produce weakness or fatigue.

Severe systemic illness affecting life-expectancy.

Trial design

Treatments tested in this trial

  • Drug treatment of myasthenia gravis and treatment of crisis

Treatment groups

No treatment groups listed

Sponsors and collaborators

Assiut University

Lead sponsor

Source ClinicalTrials.gov